Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 4/20 | 0.60 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.60 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.60 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.60 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.60 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.60 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.60 |
| ▸ | MARK3 | P27448 | 10/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.60 |
| ▸ | GSK3A | P49840 | 3/20 | 0.60 |
| ▸ | GSK3B | P49841 | 3/20 | 0.60 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.60 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.60 |
| ▸ | FLT1 | P17948 | 2/20 | 0.60 |
| ▸ | FLT4 | P35916 | 2/20 | 0.60 |
| ▸ | CDK2 | P24941 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | CLK2 | P49760 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31487768 | 0.80 | RET (0.48) | PRKAG1PRKAA1PRKAB1MARK3KDR | |
| SCHEMBL31201612 | 0.80 | AURKB (0.44) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL25297418 | 0.80 | PRKAB2 (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL13126003 | 0.79 | PRKAB1 (0.72) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL17442241 | 0.76 | PRKAB1 (0.59) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL22792505 | 0.75 | USP30 (0.42) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL2813127 | 0.75 | PRKAB1 (1.00) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL19110545 | 0.75 | PRKAB1 (0.67) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL2810629 | 0.75 | KDR (1.00) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL19110525 | 0.75 | PRKAB1 (0.67) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-3904355-B1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220098204-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3904355-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2021-11-03 | — | — | EP | disclosed |
| WO-2020249096-A1 | FUSED RING COMPOUND AS FGFR AND VEGFR DUAL INHIBITOR | 南京明德新药研发有限公司 | 2020-12-17 | — | — | WO | disclosed |
| EP-2178375-B1 | PYRAZOLOÝ1,5-A¨PYRIMIDINE DERIVATIVES | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8461162-B2 | Pyrazolo[1,5-a]pyrimidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20100305091-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | MERCK SHARP & DOHME LLC | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098204-A1 | SUBSTITUTED FUSED AROMATIC RING DERIVATIVE, COMPOSITION AND USE THEREOF | BRAF, ALK, TYRO3 | PRKAG1 1770/4885PRKAA1 1080/4885PRKAB1 1654/4885 |
| US-20100305091-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | MAPT, TTBK1, TTBK2 | PRKAG1 441/4885PRKAA1 525/4885PRKAB1 450/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | PRKAG1 406/4885PRKAA1 1415/4885PRKAB1 640/4885 |
| US-12365685-B2 | Substituted fused aromatic ring derivative, composition and use thereof | BRAF, ALK, TYRO3 | PRKAG1 1770/4885PRKAA1 1080/4885PRKAB1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.